Latest Headlines

  1. Ensorcell Appoints Biopharma Industry Veterans Geoff Hodge And Amy Teachout To Senior Leadership Team 3/3/2026

    Ensorcell, a company focused on reimaging life science tools and solutions for the biopharmaceutical industry, today announced the appointment of Geoff Hodge and Amy Teachout to its senior leadership team. These appointments reinforce Ensorcell’s commitment to innovation, superb value, and exceptional customer experience as the company continues to expand its capabilities and partnerships across the biopharma ecosystem.

  2. Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas 2/26/2026

    Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. 

  3. Andelyn Biosciences To Apply the AAV Curator® Platform To Manufacture Clinical Grade AAV For Drake Rayden Foundation For The Treatment Of Nonketotic Hyperglycinemia 2/25/2026

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator® Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene.

  4. Nu-Tek BioSciences Reinforces Global Supply Leadership With Halal Certification Renewal 2/25/2026

    Nu-Tek BioSciences, the industry leader in 100% animal-origin-free (AOF) peptones and yeast extracts, announced today that it has successfully renewed its Halal certification from The Islamic Food and Nutrition Council of America (IFANCA).

  5. Nu-Tek BioSciences To Highlight Animal-Origin-Free Peptones, Supply Chain Strength At DCAT Week 2026 2/25/2026

    Nu-Tek BioSciences, the market leader in 100% animal-origin-free (AOF) peptones and yeast extracts, announced today that it will participate in the upcoming Drug, Chemical and Associated Technologies (DCAT) Week 2026, hosted March 23–26 in New York City. 

  6. Minaris And Genetix Biotherapeutics Expand Manufacturing Partnership To Support Commercial Supply For LYFGENIA™ (lovotibeglogene autotemcel) 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced an expanded manufacturing partnership to increase commercial-scale production of LYFGENIA, Genetix’s FDA-approved, one-time gene therapy for individuals 12 years and older with sickle cell disease.

  7. Minaris Announces Viral Clearance Laboratory Upgrade at Philadelphia Campus 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an upgrade to its Viral Clearance laboratory capabilities at its Philadelphia campus.

  8. Minaris Joins CIRM Industry Resource Partner Program 2/24/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced that it has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program.

  9. Johnson & Johnson Announces $1 Billion Investment With New Cell Therapy Manufacturing Facility In Pennsylvania 2/22/2026

    ohnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

  10. Esco Philippines Returns To The 41st PSNM Annual Convention: Supporting Innovation In Nuclear Medicine 2/19/2026